Provided by Tiger Fintech (Singapore) Pte. Ltd.

Park Hotels & Resorts Inc.

11.18
+0.01000.09%
Post-market: 11.300.1199+1.07%16:51 EDT
Volume:4.13M
Turnover:46.26M
Market Cap:2.23B
PE:18.35
High:11.29
Open:11.20
Low:11.08
Close:11.17
Loading ...

Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting

GlobeNewswire
·
24 Apr

Morgan Stanley Cuts Price Target on Park Hotels & Resorts to $10 From $12, Keeps Equalweight Rating

MT Newswires Live
·
22 Apr

Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite’s Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

GlobeNewswire
·
17 Apr

Aptar Announces Clinical Validation Study to Accelerate US FDA Approval of SmartTrack™ In-Vitro-in-Silico Platform for Pressurized Metered-Dose Inhalers

Business Wire
·
16 Apr

MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability

PR Newswire
·
15 Apr

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

GlobeNewswire
·
07 Apr

Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

GlobeNewswire
·
04 Apr

Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)

GlobeNewswire
·
03 Apr

Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference

GlobeNewswire
·
02 Apr

COCP: Norovirus Challenge Study Planned for 2025…

Zacks Small Cap Research
·
01 Apr